Lexeo Therapeutics, Inc. announced it has entered into a common stock purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 6,278,905 shares of its common stock at an issue price of $15.13 per share for gross proceeds of $95,000,000 on March 11, 2024. the transaction will include participation from Braidwell LP, Adage Capital Partners LP, RA Capital Management, Surveyor Capital, Eventide Asset Management and Novo Holdings A/S. The transaction is expected to close on March 13, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.42 USD | +2.17% | +0.76% | -0.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.82% | 433M | |
+26.52% | 44.96B | |
-0.69% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.48% | 26.08B | |
-21.09% | 19.03B | |
+6.13% | 12.75B | |
+28.39% | 12.06B | |
-3.21% | 11.75B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding